Concepedia

Author

Pierre Sesques

Hospices Civils de LyonORCID

Also Known As

G. Salles, P Sesques, P. SESQUES, P. Sesques, Pierre P Sesques, Pierre SESQUES, Pierre Sesques, Sesques, Pierre

131

Publications

2.7K

Citations

22

H-Index

38

Concepts

All Affiliations

Hospices Civils de LyonInsermUniversité Claude Bernard Lyon 1Centre Hospitalier Universitaire de NantesAssistance Publique – Hôpitaux de Paris
PS

About

Pierre Sesques is an author at Hospices Civils de Lyon specializing in medicine, immunology, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

664

2

Health Sciences

3

3

137

3

Cellular Therapies

2

2

221

4

Clinical Immunology

2

2

115

5

Cell Biology

1

1

21

Pierre Sesques

×

33

Publications

2.3K

Citations

21

H-Index

YearCitations

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Kai Rejeski, Ariel Perez Perez, Pierre Sesques,

Blood

2021

398

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi,

Nature Medicine

2022

343

Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas

Ryan D. Morin, Sarit Assouline, Miguel Alcaide,

Clinical Cancer Research

2015

221

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy,

Blood

2022

131

Commercial <scp>anti‐CD19 CAR</scp> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center

Pierre Sesques, Emmanuelle Ferrant, Violaine Safar,

American Journal of Hematology

2020

130

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Anne M. Spanjaart, Per Ljungman, Rafael de la Cámara,

Leukemia

2021

112

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

Kai Rejeski, Doris K. Hansen, Radhika Bansal,

Journal of Hematology & Oncology

2023

95

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

Élie Azoulay, Pedro Castro, Adel Maamar,

The Lancet Haematology

2021

91

Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells

Pierre Sesques, Jérémie Tordo, Emmanuelle Ferrant,

Clinical Nuclear Medicine

2021

78

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

Jean Lemoine, Emmanuel Bachy, Guillaume Cartron,

Blood Advances

2023

68

Page 1